What You Should Know
- The FDA has launched two proof-of-concept (PoC) real-time clinical trials (RTCT) that report endpoints and data signals to the agency as they occur.
- AstraZeneca is leading a Phase 2 trial (TRAVERSE) for mantle cell lymphoma, while Amgen is conducting a Phase 1b trial (STREAM-SCLC) for small cell lung carcinoma.
- The initiative aims to eliminate the traditional “hiatus” between clinical phases, moving toward a model of “continuous” trials that reduces regulatory lag.
- A Request for Information (RFI) has been issued to seek industry input on a broader pilot program launching this summer; comments are being accepted through May 29, 2026.
- Technical feasibility has already been established, with the FDA successfully receiving and validating real-time signals from AstraZeneca’s trial via Paradigm Health.
For over six decades, the clinical trial ecosystem has operated under a model where critical safety and efficacy data can take years to reach regulatory eyes. This lag often serves as a primary bottleneck in drug development, delaying access to potentially life-saving treatments. Today, the U.S. Food and Drug Administration (FDA) signaled a fundamental shift in this paradigm by announcing the initiation of real-time clinical trials (RTCT), a modern approach powered by AI and advanced data science that allows agency scientists to monitor endpoints and safety signals as a trial progresses.
The goal of this initiative is to move beyond the discrete, siloed phases that currently define drug development. In the traditional model, a hiatus occurs after each phase as sponsors analyze data and submit it to the FDA for review before beginning the next study. RTCT allows for “continuous” trials, where the visibility of key insights in real time could reduce these delays to a minimum, radically increasing the efficiency of the entire development timeline.
Industry Leaders Pioneer the Real-Time Framework
The FDA is launching this initiative with high-profile collaborations involving AstraZeneca and Amgen. AstraZeneca’s Phase 2 TRAVERSE trial, focused on treatment-naïve mantle cell lymphoma, is already yielding validated signals through the Paradigm Health technical framework. This multi-site study involves prestigious academic partners, including The University of Texas MD Anderson Cancer Center and the University of Pennsylvania.
Simultaneously, Amgen is initiating the STREAM-SCLC trial, a Phase 1b study for limited-stage small cell lung carcinoma. For both projects, the FDA and sponsors have established strict criteria for what constitutes a “real-time signal.” Chief AI Officer Jeremy Walsh noted that these PoCs demonstrate that real-time monitoring is no longer just a theoretical concept but a transformative reality that prioritizes the patient awaiting a powerful treatment.
Scaling the Vision: The RFI and Future Pilot Program
Building on the early successes of AstraZeneca and Amgen, the FDA has released a Request for Information (RFI) to inform a broader pilot program. The agency is seeking input from stakeholders on potential program designs, implementation strategies, and success metrics. This open call for information reflects the FDA’s commitment to building a technical and regulatory infrastructure that can be adopted across all phases of drug development.
The agency has established an aggressive timeline for the remainder of 2026. Following the May 29 deadline for RFI comments, the FDA intends to disseminate final selection criteria in July and complete selections for the pilot program in August. This structured rollout is intended to provide health systems, sponsors, and trial sites with a clear roadmap for integrating real-time reporting into their clinical workflows.
Why This Matters
The success of AstraZeneca’s trial using Paradigm Health highlights that the infrastructure used to move and validate data is now as critical as the therapy itself. If the FDA successfully scales this pilot, we are looking at the most significant regulatory disruption since the inception of the phased trial model—one that could shave years off the drug approval cycle.
